Skip to content
MarketScale
‹ Back to IndustriesSciences

Semi-Living Cyborg Cells Generate Hope Within the Scientific Medical Community

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By James Kent · Andrew AijianBiomedical EngineeringCyborg CellsDecibio
Share

Key takeaways

01

Did James Cameron see the future back in 1984?

02

The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide…

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide and grow.

“The cyborg cells are programmable, do not divide, and preserve essential cellular activities and gain non-native abilities,” said biomedical engineer Cheemeng Tan from the University of California, Davis.

Biomedical advancements, such as the use of AI and cell therapy, bring with them the potential for myriad applications. One such promising application is the use of cyborg cells in oncology. Lab testing on tissue samples is underway, and the hope is cyborg cells could one day be used to deliver drugs to specific parts of the body.

Where might this technology take science in the coming years? Stephane Budel, Ph.D., a Founding Partner at DeciBio, and Andrew Aijian, Ph.D., a Partner at DeciBio, a strategy and market intelligence company for the precision medicine industry, provided some clues.

Stephane and Andrew’s Thoughts

This is a very exciting paper. The advance of cyborg cells can have several therapeutic applications. A clear one is in oncology. There has been a lot of exciting development recently with CAR Ts. And people are discussing is it going to be autologous cells that come from the patient or allogeneic cells that would be easier to work with, where you would have like a massive batch of cells that you can use.

And there is now a third type of cells you could use: cyber cells. And in this case, you add synthetic polymers. The cells retain a number of functions, but they stop dividing. You can imagine people starting to be looking at a variety of different types of polymers and a variety of different types of synthetic pathways that they do to address cancer cells and beyond.” – Budel

Yeah, this is the first I’ve been exposed to cyborg cells. The first I’m hearing of it. And I think what will be interesting is to see how this approach gets applied to different cell types; bacterial cells, human cells, cells with different functionalities, et cetera. And you can sort of really start to explore a vast space of possibilities and how you can use these types of cells for health applications, synthetic biology, industrial applications, especially if you can introduce non-native capabilities. In the paper, they cited the ability of these cells to be more resistant to peroxide environments, which has implications in industrial applications.

There’s sort of a huge space of functionalities and capabilities that you can explore. And I’m sure that researchers will be spending a lot of time optimizing the cells and the conditions to create many novel functionalities.” – Aijian

Something we discussed as well is the need for these cells to actually evade the immune system. And there is certainly something that you can engineer in these cells as well that will be important if you want to inject them back into humans to treat virus conditions.” – Budel

About the author

JK
James KentPodcast Host and Content Creator

Dependable leader and Podcaster with more than 12 years of results-oriented brand marketing and agency management experience including a broad range of competencies: Adaptive communication and presentation skills. A manager who coaches, mentors and leads. Ability to successfully work cross-functionally within every level of an organization. Strong focus on innovative marketing solutions. Outstanding client relationship building and strategic account management support. Thrives in fast-paced environments with multiple deliverables. Podcast host and content creator.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

JK
James Kent

Podcast Host and Content Creator

Dependable leader and Podcaster with more than 12 years of results-oriented brand marketing and agency management experience including a broad range of competencies: Adaptive communication and presentation skills. A manager who coaches, mentors and leads. Ability to successfully work cross-functionally within every level of an organization. Strong focus on innovative marketing solutions. Outstanding client relationship building and strategic account management support. Thrives in fast-paced environments with multiple deliverables. Podcast host and content creator.